Latest Regulatory Submissions News

Vysarn Limited has reported a record first half for FY26 with revenue hitting $66.8 million and NPBT nearly doubling year-on-year to $10 million. The company reaffirms its full-year $20 million NPBT target, supported by strong industrial and advisory segment growth despite timing challenges in technology projects.

BPH Energy Ltd reported a half-year net loss of $925,691, weighed down by investment write-downs and associate losses, while raising $1.2 million to fund exploration and development. The company’s future hinges on a Federal Court review of a critical offshore permit held by investee Advent Energy.

Nexalis Therapeutics has completed a key capital raising milestone, issuing new shares, options, and performance rights following shareholder approval. This move supports the company’s clinical-stage drug development programs targeting pain and mental health.

Native Mineral Resources has successfully poured 1,543 ounces of gold doré at its Blackjack Processing Plant, while progressing key operational and regulatory initiatives to optimise mining and processing activities.

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

A single exploration name blew the doors off the leaderboard, while two well-known uranium plays and a Nevada explorer sank hard. Behind the noise: deals got closer to completion, big raisings reset prices, and several “good news” gaps didn’t survive the week.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Memphasys has raised $800,000 through a share placement to accelerate the commercial expansion of its Felix™ System, following key regulatory approvals and initial revenue milestones.

OncoSil Medical Ltd has launched an $8 million equity raising to fund the commercial expansion and clinical development of its targeted radiotherapy device for pancreatic cancer, aiming to capitalise on growing European market adoption and upcoming trial catalysts.

OncoSil Medical secures $8 million in capital to fund a pivotal German government-sponsored clinical trial and accelerate its European commercial expansion.

Memphasys has lodged regulatory submissions for its Felix™ System in Australia and India, following CE Mark approval, while progressing UK market entry under the CE Mark transition framework.